GLIS3-AS1: A Potential Drug Target and Biomarker (G84850)

Target Name: GLIS3-AS1

NCBI ID: G84850

GLIS3-AS1

Other Name(s): GLIS3 antisense RNA 1 | C9orf70

GLIS3-AS1: A Potential Drug Target and Biomarker

GLIS3-AS1, a highly conserved RNA molecule located in the gene GLIS3 (Gliadhera grandiflorum-specific insulin gene), has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure, stability, and expression patterns make GLIS3-AS1 an attractive candidate for further investigation.

GLIS3-AS1 is a small non-coding RNA molecule that contains 194 amino acid residues. It is expressed in various tissues and cells of the body and is primarily localized to the cytoplasm. GLIS3-AS1 has been shown to play a critical role in regulating insulin sensitivity and glucose metabolism.

GLIS3-AS1 has been linked to several diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. Its expression patterns and functions have been observed in various disease models, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, GLIS3-AS1 has been shown to be involved in the regulation of cell growth, apoptosis, and angiogenesis. It has been shown to promote the growth and survival of cancer cells, and to inhibit the anti-tumor effects of various therapeutic approaches.

In neurodegenerative diseases, GLIS3-AS1 has been linked to the regulation of neurotransmitter synthesis and release, as well as the maintenance of neuronal structure and function. Its expression patterns have been observed in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In autoimmune disorders, GLIS3-AS1 has been shown to play a role in the regulation of immune cell function and the development of autoimmune diseases. Its expression patterns have been observed in various autoimmune disorders, including rheumatoid arthritis, multiple sclerosis, and Crohn's disease.

GLIS3-AS1 has also been shown to have potential as a biomarker for various diseases. Its expression patterns have been used to diagnose and monitor the progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, GLIS3-AS1 has been shown to be a potential biomarker for cancer, as its expression patterns have been associated with the severity of cancer-related symptoms.

Despite its potential as a drug target and biomarker, GLIS3-AS1 has not yet been fully characterized. Further research is needed to fully understand its role in various diseases and conditions.

In conclusion, GLIS3-AS1 is a promising candidate for further investigation as a drug target and biomarker. Its unique structure, stability, and expression patterns make it an attractive candidate for further study. Further research is needed to fully understand its role in various diseases and conditions.

Protein Name: GLIS3 Antisense RNA 1

The "GLIS3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GLIS3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets